Takeda vs GSK vs Pfizer and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q3 2026: Takeda 7.597, GSK 11.109, Pfizer 16.583, Merck & Co. 18.085.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Takeda, GSK, Pfizer, Merck & Co..| Metric | Takeda | GSK | Pfizer | Merck & Co. |
|---|---|---|---|---|
| Market Cap | $69.14B | $98.70B | $162.27B | $353.44B |
| Revenue | $7.60B | $11.11B | $16.58B | $18.09B |
| Cost of Revenue | $2.51B | $2.84B | $4.03B | $4.89B |
| Gross Profit | $5.09B | $8.27B | $12.55B | $13.19B |
| Operating Income | $1.31B | $3.21B | $3.67B | $5.59B |
| Net Income | $1.23B | $1.93B | $3.24B | $5.07B |
| R&D Expense | $1.10B | $2.34B | $3.02B | $4.54B |
| Earnings Per Share | $0.38 | $0.96 | $0.56 | $2.04 |
| Gross Margin | 67.0% | 74.5% | 75.7% | 73.0% |
| Operating Margin | 17.3% | 28.9% | 22.1% | 30.9% |
| Net Profit Margin | 16.2% | 17.4% | 19.6% | 28.0% |
| Free Cash Flow | $1.36B | $3.04B | $4.80B | $5.52B |
| Cumulative Free Cash Flow | $35.42B | $160.25B | $361.51B | $255.22B |
| Operating Cash Flow | $1.65B | $3.51B | $5.38B | $6.56B |
| Cash & Equivalents | $2.68B | $3.72B | $1.82B | $9.55B |